AR antagonist 15
AR antagonist 15 is an orally active androgen receptor (AR) antagonist with the IC50 of 97 nM for ART787A. AR antagonist 15 disrupts AR nuclear translocation, hinders AR homodimerization, and suppresses transcription of AR-regulated genes by competitive binding to the ligand binding pocket. AR antagonist 15 can significantly lower the prostate-specific antigen (PSA) level. AR antagonist 15 induces apoptosis by reducing the expression of apoptosis pathway related proteins. AR antagonist 15 can be used for the research of prostate cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1790308-86-9
- Formel: C18H22N2O3S
- Molecular Weight:346.44
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
AR antagonist 15 (Compound LT16) has significant antagonistic activity against androgen receptors (AR) and and its relevant mutants, including ART787A (IC50 = 97 nM), ARF877L (IC50 = 200 nM), ARF877L/T787A (IC50 = 260 nM), ARH875Y/T787A (IC50 = 200 nM), ARW742C (IC50 = 510 nM) and ART787G (IC50 = 555 nM)[1].
AR antagonist 15 reduces the prostate-specific antigen (PSA) levels secreted in a dose dependent manner with the IC50 of 0.16 μM[1].
AR antagonist 15 (48 h) impeds the translocationof AR from the cytoplasm to the nucleus[1].
AR antagonist 15 (0.1-10 μM, 48 h) can downregulate the mRNA level of AR regulated genes and significantly lowers the mRNA level of key proteins involved in the apoptosis pathway in LNCaP cells[1].
AR antagonist 15 (0.01-100 μM; 3 days or 5 days) significantly inhibits the AR positive cells proliferation[1].
AR antagonist 15 (10 μM, 48 h) induces G0/G1 cell cycle arrest in LNCaP cells[1].
AR antagonist 15 (0.5-5 μM, 14 days) inhibits the growth of LNCaP cells and reduces the number of cell colonies[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LNCaP cells
-
Concentration:0.1 μM, 1 μM, 10 μM, Enzalutamide (Enz) (HY-70002) as a control group
-
Incubation Time:48 h
-
Result:Reduced the level of protein TMPRSS2, FKBP5, and PSA.
-
Cell Line:LNCaP cells
-
Concentration:0.1 μM, 1 μM, 10 μM
-
Incubation Time:48 h
-
Result:Reduced the mRNA level of AR regulated genes KLK3, TMPRSS2, FKBP5, c-MYC and UBE2C.
Lowed the mRNA level of proteins related to the apoptosis pathway Cyclin A, CDK1, CDC20, and CKS2.
-
Cell Line:LNCaP, LNCaP-CRPC, LNCaP-EnzR, VCaP, 22Rv1, and C4-2B cells
-
Concentration:5 days for LNCaP and LNCaP-CRPC cells; 3 days for LNCaP-EnzR, VCaP, 22Rv1, and C4-2B cells
-
Incubation Time:48 h
-
Result:Exhibited a relatively better antiproliferative effect in LNCaP (IC50 = 5.31 μM), LNCaP-CRPC (IC50 = 8.05 μM) and LNCaP-EnzR (IC50 = 5.40 μM).
-
Cell Line:LNCaP cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Caused cell cycle arrest in G0/G1.
-
Cell Line:LNCaP cells
-
Concentration:0.5 μM, 10 μM
-
Incubation Time:14 days
-
Result:Significantly inhibited the number of cell colonies.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×107 LNCaP cells injected the Balb/C nude male mice (4-6 weeks)[1]
-
Dosage:50 mg/kg
-
Administration:Oral gavage (i.g.); once daily for three weeks
-
Result:Significantly reduced tumor volume and tumor weight of the cancer mice and the final tumor growth inhibition (TGI) rate was 75.63%.
Significantly inhibited the PSA level and the concentration of the PSA droped to 11.08 ng/mL. Did not cause significant changes in the weight of the mice.
Chemical Information
-
CAS. Nr. 1790308-86-9
-
Molecular Weight 346.44
-
Formel C18H22N2O3S
-
SMILES
O=S(NC1=CC=C(C=C1)OCC2=CC=CC=C2)(N3CCCCC3)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)